Apellis Pharmaceuticals Profit Margin

The latest profit margin for APLS is 17.98% as of March 2026. That compares with -30.43% in the prior-year period — up 159.1% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Apellis Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, APLS's profit margin moved from -30.43% to 17.98% — a 159.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Apellis Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, APLS currently prints 17.98% for profit margin, while the sector average sits near 13.89%. That is roughly 29.4% above the sector mean. Large gaps often invite a closer look at Apellis Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Apellis Pharmaceuticals converts resources into returns. At 17.98%, APLS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -30.43% in the prior-year period — up 159.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting APLS's profit margin (17.98%), review year-over-year change from -30.43%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.